Literature DB >> 17380077

Expression of ErbB receptor proteins and TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver.

Tae Yeong Lee1, Kyoung-Tae Kim, Sang-Young Han.   

Abstract

BACKGROUND AND AIMS: ErbB receptor proteins are transmembrane tyrosine kinase receptors; when they are activated by interaction with ligands, they generate diverse cellular responses, especially during lesion development and progression to cancer. In this study the expression of ErbB receptors and TGF-alpha were investigated using an experimental cirrhosis rat model giving rise to hepatocellular neoplasms, similar to human liver diseases.
METHODS: Fifty three male rats received intraperitoneal injection of diethylnitrosamine (DEN, 50 mg/kg), weekly for 18 weeks. Until the eighth week, two rats were sacrificed every two weeks and from the tenth to the eighteenth week, five rats were sacrificed weekly. Grossly, dyschromatic and dysmorphic nodules were counted and categorized into three groups: N1/N2/N3: 3 mm < or = x < 5 mm/5 mm < or = x < 10 mm/x > or = 10 mm in diameter. All nodules were examined, histologically. Antibodies for GSTp, TGF-alpha, EGF-R, ErbB2, ErbB3 and ErbB4 were used for immunohistochemistry.
RESULTS: The onset of cirrhoses was noted from the twelfth week. Preneoplastic foci, hepatocellular adenomas (HCA) and hepatocellular carcinomas (HCC) were noted from the second, eleventh and fifteenth week, respectively. The nodules (N1/N2/N3: 397/258/64) included regenerating nodule; RN (N1/N2/N3: 72.3%/15.9%/0%), HCA (N1/N2/N3: 27.2%/82.2%/7.6%) and HCC (N1/N2/N3: 0.5%/ 1.9%/92.4%). EGF-R was expressed in 12.5% of RN, 64.7% HCA and 75.2% HCC. TGF-alpha was expressed in 92.4% of RN, 91.3% HCA and 93.2% HCC. Sixty eight percent of TGF-alpha expressing nodules showed concurrent EGF-R expression. ErbB2 was expressed in 83.6% of RN, 72.9% HCA and 88.7% HCC. ErbB4 was expressed in 95.2% of RN, 86.3% HCA and 62.5% HCC.
CONCLUSIONS: Increased expression of EGF-R and decreased expression of ErbB4, might be related with tumor progression during DEN-induced hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17380077

Source DB:  PubMed          Journal:  Korean J Hepatol        ISSN: 1738-222X


  5 in total

Review 1.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

2.  Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.

Authors:  Bryan C Fuchs; Yujin Hoshida; Tsutomu Fujii; Lan Wei; Suguru Yamada; Gregory Y Lauwers; Christopher M McGinn; Danielle K DePeralta; Xintong Chen; Toshihiko Kuroda; Michael Lanuti; Anthony D Schmitt; Supriya Gupta; Andrew Crenshaw; Robert Onofrio; Bradley Taylor; Wendy Winckler; Nabeel Bardeesy; Peter Caravan; Todd R Golub; Kenneth K Tanabe
Journal:  Hepatology       Date:  2014-02-28       Impact factor: 17.425

3.  The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma.

Authors:  Nuray Bassullu; Ilknur Turkmen; Murat Dayangac; Pinar Yagiz Korkmaz; Reyhan Yasar; Murat Akyildiz; Onur Yaprak; Yaman Tokat; Yildiray Yuzer; Gulen Bulbul Dogusoy
Journal:  Hepat Mon       Date:  2012-10-11       Impact factor: 0.660

4.  High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma.

Authors:  Xiao-Yan Duan; Qin Pan; Shi-Yan Yan; Wen-Jin Ding; Jian-Gao Fan; Liang Qiao
Journal:  BMC Gastroenterol       Date:  2014-11-20       Impact factor: 3.067

5.  Oldenlandia diffusa Promotes Antiproliferative and Apoptotic Effects in a Rat Hepatocellular Carcinoma with Liver Cirrhosis.

Authors:  Yun-Young Sunwoo; Jin-Hee Lee; Ho Yong Jung; Yu Jin Jung; Moon-Seo Park; Yong-An Chung; Lee-So Maeng; Young-Min Han; Hak Soo Shin; Jisoo Lee; Sang In Park
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-10       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.